OR WAIT null SECS
May 05, 2020
Trial begins in the US for the Pfizer-BioNTech mRNA COVID-19 vaccine; manufacturing plans announced.
The extension of the company’s product offerings to include the anti-certolizumab pegol antibodies offers critical reagents for the development of assays for TNF alpha inhibitor biologics and their biosimilars.
April 16, 2020
This milestone achievement will allow the companies to move forward with developing a GMP-compliant manufacturing process for clinical testing.
April 14, 2020
With the acquisition, Orgenesis will combine TamirBio’s ranpirnase antiviral platform with its Bioxome technology.
April 09, 2020
The partners have formed a joint venture to produce muscle-derived mesenchymal stem cells as a source of exosomes and other cellular products to develop related therapies and advance clinical trials.
April 08, 2020
Industry opportunities are increasing for biosimilars, but companies should pay close attention to delivery device design to facilitate success.
April 02, 2020
FDA is encouraging alternative insulins and challenging anticompetitive practices.
Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.
Because conventional cleaning methods can risk product loss, biopharmaceutical manufacturers are often reluctant to use PDE/ADE limits to validate cleaning processes.
But are innovations sufficient to increase adoption? CMOs are demanding better continuous bioprocessing options.